| Primary |
| Product Used For Unknown Indication |
37.8% |
| Heparin-induced Thrombocytopenia |
17.6% |
| Anticoagulant Therapy |
8.6% |
| Drug Use For Unknown Indication |
7.7% |
| Thrombosis Prophylaxis |
5.4% |
| Prophylaxis |
3.6% |
| Thrombocytopenia |
3.2% |
| Pulmonary Embolism |
2.3% |
| Cardiac Failure |
1.8% |
| Disseminated Intravascular Coagulation |
1.8% |
| Sepsis |
1.8% |
| Antibiotic Therapy |
1.4% |
| Atrial Fibrillation |
1.4% |
| Cardiac Valve Prosthesis User |
1.4% |
| Cerebral Ischaemia |
0.9% |
| Heart Valve Replacement |
0.9% |
| Peripheral Ischaemia |
0.9% |
| Venous Thrombosis |
0.9% |
| Aortic Thrombosis |
0.5% |
| Arteriogram Coronary |
0.5% |
|
| Thrombocytopenia |
22.2% |
| Toxic Skin Eruption |
9.3% |
| Cerebral Haematoma |
5.6% |
| Haemorrhage |
5.6% |
| Heparin-induced Thrombocytopenia |
5.6% |
| Blood Pressure Decreased |
3.7% |
| Condition Aggravated |
3.7% |
| Death |
3.7% |
| Embolism |
3.7% |
| Knee Arthroplasty |
3.7% |
| Renal Failure |
3.7% |
| Shock Haemorrhagic |
3.7% |
| Splenic Haemorrhage |
3.7% |
| Systemic Lupus Erythematosus |
3.7% |
| Thrombophlebitis Superficial |
3.7% |
| Thrombosis |
3.7% |
| Transaminases Increased |
3.7% |
| Underdose |
3.7% |
| Abdominal Wall Haematoma |
1.9% |
| Anaemia |
1.9% |
|
| Secondary |
| Product Used For Unknown Indication |
31.0% |
| Drug Use For Unknown Indication |
19.6% |
| Heparin-induced Thrombocytopenia |
12.0% |
| Thrombosis Prophylaxis |
7.6% |
| Anticoagulant Therapy |
5.4% |
| Pulmonary Embolism |
2.7% |
| Acute Lymphocytic Leukaemia |
2.2% |
| Cardiac Failure |
2.2% |
| Cardiopulmonary Bypass |
2.2% |
| Infection |
2.2% |
| Phlebitis |
2.2% |
| Pneumococcal Infection |
2.2% |
| Prophylaxis |
2.2% |
| Deep Vein Thrombosis |
1.6% |
| Bronchopneumopathy |
1.1% |
| Cerebral Ischaemia |
1.1% |
| Ischaemic Stroke |
1.1% |
| Anticoagulation Drug Level |
0.5% |
| Aortic Thrombosis |
0.5% |
| Aspergillus Infection |
0.5% |
|
| Pancreatitis |
16.3% |
| Thrombocytopenia |
16.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
6.1% |
| Intra-abdominal Haematoma |
6.1% |
| Pulmonary Embolism |
6.1% |
| Renal Failure |
6.1% |
| Splenic Haemorrhage |
6.1% |
| Coma |
4.1% |
| Heparin-induced Thrombocytopenia |
4.1% |
| Tachycardia |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Upper Gastrointestinal Haemorrhage |
4.1% |
| Alanine Aminotransferase Increased |
2.0% |
| Cerebral Haemorrhage |
2.0% |
| Death |
2.0% |
| Deep Vein Thrombosis |
2.0% |
| Haematuria |
2.0% |
| Haemorrhagic Disorder |
2.0% |
| Medication Error |
2.0% |
| Melaena |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
20.7% |
| Prophylaxis |
17.7% |
| Product Used For Unknown Indication |
12.8% |
| Infection Prophylaxis |
7.5% |
| Multiple Myeloma |
6.9% |
| Pneumonia |
6.3% |
| Unevaluable Event |
3.1% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Hypertension |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Allogenic Bone Marrow Transplantation Therapy |
2.3% |
| Disseminated Intravascular Coagulation |
2.3% |
| Acute Myeloid Leukaemia |
2.2% |
| Infection |
2.1% |
| Immunosuppression |
1.7% |
| Neoplasm Malignant |
1.6% |
| Ill-defined Disorder |
1.4% |
| Pain |
1.3% |
| Bone Marrow Transplant |
1.1% |
| Febrile Neutropenia |
1.0% |
|
| White Blood Cell Count Decreased |
13.2% |
| Thrombocytopenia |
10.7% |
| Renal Impairment |
8.3% |
| Sepsis |
7.4% |
| Ventricular Tachycardia |
7.4% |
| Septic Shock |
6.6% |
| Tumour Lysis Syndrome |
6.6% |
| Vomiting |
5.8% |
| Urinary Tract Infection |
4.1% |
| Venoocclusive Liver Disease |
4.1% |
| Pyrexia |
3.3% |
| Tremor |
3.3% |
| Ileus Paralytic |
2.5% |
| Multi-organ Failure |
2.5% |
| Pleural Effusion |
2.5% |
| Post Procedural Haemorrhage |
2.5% |
| Pulmonary Alveolar Haemorrhage |
2.5% |
| Renal Haematoma |
2.5% |
| Urticaria |
2.5% |
| Gastrointestinal Haemorrhage |
1.7% |
|
